Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44 by Barbara Cuccu et al.
RESEARCH ARTICLE Open Access
Identification of a human immunodominant T-cell
epitope of mycobacterium tuberculosis antigen
PPE44
Barbara Cuccu, Giulia Freer, Alessandro Genovesi, Carlo Garzelli and Laura Rindi*
Abstract
Background: Recently our group has identified a novel antigen of Mycobacterium tuberculosis, protein PPE44,
belonging to the “PPE protein” family. Although its role in infection is largely unknown, PPE44-specific immune
responses were detected in mice infected with M. tuberculosis; moreover, immunization of mice with PPE44
subunit vaccines resulted in protective efficacy comparable to the one afforded by BCG against M. tuberculosis
(Romano et al., Vaccine 26, 6053-6063, 2008).
Results: In the present paper, we investigated anti-PPE44 T-lymphocyte responses during human infection by
evaluating the frequency of PPE44-specific interferon (IFN)-g-secreting cells by ELISpot and flow cytometry in a
small cohort of healthy subjects that had proven positive to PPD (PPD+) in vitro, in patients with active
tuberculosis, in subjects vaccinated with BCG and in unvaccinated, PPD- healthy controls. We showed IFN-g+ T cell
immune responses to recombinant PPE44 in at least a very high proportion of PPD+ individuals tested and, to a
lower extent, in subjects vaccinated with BCG. By the use of a panel of overlapping synthetic 20-mer peptides
spanning the PPE44 primary amino acid sequence, we identified a strong CD4+ T-cell epitope, encompassed by
peptide p1L (VDFGALPPEVNSARMYGGAG), in the NH2-terminus of the PPE44 molecule at the amino acid position
1-20. Conversely, our experiments did not provide evidence of a significant IFN-g+ CD4+ T cell response to PPE44
or its immunodominant peptide p1L in most (7 out of 8) patients with active TB.
Conclusions: Our data suggest an important immunological role of PPE44 and its immunodominant epitope p1L
that could be useful in the design of anti-tuberculosis vaccines and in the immunological diagnosis of M.
tuberculosis infection.
Background
Tuberculosis (TB) is the most significant bacterial infec-
tion of humans worldwide involving an estimated 2 bil-
lion people, that is one third of the world’s population
[1]. The host’s immune system plays a central role in the
progression of TB infection; it is in fact estimated that
about 5-10% of individuals that become infected with
Mycobacterium tuberculosis develop active pulmonary
TB and become infectious, while the large majority
develop latent infection due to the immunological con-
tainment of infection in specific granulomas where tuber-
cle bacilli do not multiply, but persist in a dormant state
without provoking any clinical symptoms [2,3]. Latent
TB may undergo reactivation when the immune system
is less efficient, for example due to HIV infection, malnu-
trition, aging or other causes. As it is estimated that 1 in
10 individuals infected with M. tuberculosis will develop
active TB in their lifetime [4], latent infection represents
a huge reservoir for new TB cases.
At present, the main strategies pursued to improve TB
control are more rapid case-finding, efficient drug treat-
ment and the development of a new TB vaccine, more
effective than the currently available Mycobacterium
bovis bacille Calmette-Guérin (BCG). There is therefore a
pressing need to detect new TB antigens to set up sensi-
tive immunological tests that may improve the identifica-
tion of latent TB and to develop effective vaccines
capable of activating the immune responses relevant for
protection. A Th1-type immune response, based on
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MHC class II-restricted M. tuberculosis-specific CD4+ T
cells producing IFN-g, is considered essential for immu-
nological containment of M. tuberculosis infection,
although different immune cell subsets, such as ab+
CD8+ or gδ+ T cells, or other unconventional T cells,
namely CD1-restricted ab+ T cells, contribute to
immune protection [5,6].
In the last years, our group has identified a novel anti-
gen of M. tuberculosis, protein PPE44 (Rv2770c), belong-
ing to the “PPE proteins”, a family of 69 polymorphic
proteins of M. tuberculosis, defined on the basis of the
amino acid (aa) motif Pro-Pro-Glu. Together with the PE
(Pro-Glu) proteins, they account for approximately 10%
of the coding capacity of M. tuberculosis genome [7]. PPE
proteins are characterized by a conserved NH2-terminus
domain of approximately 180 aa residues and a C-term-
inal domain variable in sequence and length; although
their role in M. tuberculosis infection is unknown, their
polymorphic nature suggests that they represent antigens
of immunological relevance [8]. In our past studies, we
reported that infection of mice with BCG or with M.
tuberculosis induced PPE44-specific humoral and cellular
immune responses [9,10] and, most importantly, vaccina-
tion of mice with PPE44-based subunit vaccines followed
by an intratracheal challenge with virulent M. tuberculo-
sis resulted in protective efficacy comparable to that
afforded by BCG [10]. This finding makes PPE44 a pro-
mising antigen candidate for TB subunit vaccines.
In the present work, we evaluated the cellular immune
response to PPE44 during mycobacterial infection by
determining the T-cell response to PPE44 in a small
cohort of subjects. Moreover, by the use of synthetic pep-
tides spanning the PPE44 molecule, we mapped a human
immunodominant epitope potentially useful for the
development of new subunit TB vaccines and immunolo-
gical diagnosis of TB.
Results
Human T cell response to rPPE44
We first determined the number of PBMC producing
IFN-g to recombinant PPE44 (rPPE44) by ELISpot in 5
PPD- (negative controls), 5 PPD+, 4 BCG-vaccinated
subjects and 8 patients with active TB. As shown in
Figure 1A, no IFN-g-secreting spots were observed in
any but one PPD- healthy donors; two out of 4 subjects
vaccinated with BCG responded to rPPE44 by producing
10 and 16 spots per 5 × 104 cells, respectively. All
healthy PPD+ individuals responded to rPPE44 yielding
the highest numbers (18-71) of IFN-g-secreting spots.
Importantly, for patients with active TB, the responders
to rPPE44, as well as the numbers of IFN-g SFU, were
significantly lower (P < 0.005, at least) than PPD+ sub-
jects, as only 1 of 8 responded to rPPE44 yielding rela-
tively few spots (13 SFU).
To ascertain that PPE44-specific responses were
accounted by CD4+ T cells, we performed ICC assays
measuring the frequency of PPE44-specific CD4+ T cells
producing IFN-g. As shown in Figure 1B, the frequency
of PPE44-specific CD4+ T cells producing IFN-g was
lower than cut-off in all PPD- healthy donors; 3 out of 5
PPD+ healthy donors yielded the highest positive
responses (0.46%). These results probably reflect the
lower sensitivity of flow cytometry compared to ELI-
Spot, as shown by other authors as well [11].
Human T cell responses to PPE44 synthetic peptides
The next experiments were aimed at mapping PPE44 T-
cell epitope(s) by studying T-cell immune response in 3 of
5 PPD+ healthy volunteers used in previous experiment;
the 3 subjects chosen tested positive to tuberculin-skin
Figure 1 IFN-g secretion by PBMC from PPD-, PPD+ and BCG-
vaccinated healthy donors and from patients with active TB in
the presence of rPPE44, as determined by ELISpot (panel A)
and ICC (panel B). ELISpot results are expressed as spot-forming
units (SFU) per 5 × 104 cells; SFU values above 5, indicated by a
horizontal dotted cut-off line, were considered as positive responses.
ICC flow cytometry results are expressed as the % of IFN-g+ CD4+
cells after subtracting background (% of IFN-g+ CD4+ in the
negative controls). Values above an arbitrary cut-off of 0.01% are
classified as positive.
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test and Quantiferon TB Gold test. Donors’ PBMC were
stimulated with a panel of synthetic 20-mer peptides, most
of which overlapped by 10 aa, spanning most of the 382 aa
sequence of PPE44 and peptide-specific immune
responses were then evaluated by ELISpot. As shown in
Figure 2, PBMC from all the donors reacted with control
rPPE44, as expected, generating numbers of IFN-g-specific
SFU ranging from 25 to 95 per 5 × 104 cells; only one pep-
tide, i.e., peptide p1L (VDFGALPPEVNSARMYGGAG),
spanning aa 1-20 of PPE44, was efficiently recognized by
PBMC from all the donors. With regards to the other pep-
tides tested, one donor responded weakly to p6L, p9L,
p11L, p12L, p21L, p22L and p30L, yielding 6 to 9 peptide-
specific SFU per 5 × 104 cells, while for the other donors
spots were generally lower than 5 per 5 × 104 cells or
absent for all peptides other than p1L. No IFN-g-positive
spots were observed towards p18L (SHITNPAGLAH-
QAAAVGQAG), spanning aa 171-190, in any of the
donors tested. Peptide p18L was therefore chosen as a
negative control for subsequent experiments.
These results suggested that p1L represents an immu-
nodominant T-cell epitope of protein PPE44.
Human T cell responses to p1L peptide
The T-cell immune response to p1L was then studied in
PPD-, PPD+ and BCG-vaccinated healthy individuals and
in patients with active TB by ELISpot and flow cytome-
try; PPD and ESAT-6 were included as controls. In PPD-
healthy donors, practically no IFN-g-producing cells were
observed in response to p1L, PPD and ESAT-6, as
expected (Figure 3A). Conversely, all PPD+ healthy
donors (Figure 3B) yielded the highest numbers of IFN-g-
producing cells in response to p1L (13 to 78 spots) and
PPD (12 to 58 spots); among the PPD+ healthy donors, 3
out of 5 responded to ESAT-6 (8, 18 and 51 spots,
respectively) and one donor responded to control peptide
p18L (16 spots) (Figure 3B). A weak IFN-g response was
observed to peptide p1L (11 spots) and antigen ESAT-6
(8 spots) in one of the subjects vaccinated with BCG
(Figure 3C); two subjects responded to PPD (22 and 27
spots, respectively) and one subject responded to p18L
(45 spots). In the 8 patients with active TB (Figure 3D),
the response to p1L peptide was absent or very poor, as
only one patient produced a number of IFN-g-positive
spots indicative of an immune response (13 spots). The
difference from PPD+ subjects is significant both in terms
of proportion of responders and numbers of IFN-g spots
(P < 0.005). Among TB patients, 6 and 4 subjects
responded to PPD and ESAT-6, respectively, which is not
statistically significant compared to the PPD+ group.
On the whole, results obtained by ICC (Figure 4A-D)
were comparable to those obtained by ELISpot and con-
firmed that most PPD+ patients (60% positivity by ICC ver-
sus 100% by ELISpot) had a detectable immune response
to p1L peptide, while none of the patients with active TB
exhibited a response to p1L peptide. Again, although flow
cytometry is less sensitive compared to ELISpot [11], it
proves that reacting subjects secrete IFN-g via their CD4+
T cells. In the responders, the frequency of specific IFN-g+
T cells was significantly higher than cut-off and reached
levels of 0.51%. Among BCG-vaccinated donors, a weak
response to p1L was observed in only one donor.
An example of the ICC analysis for peptide p1L and
rPPE44 of PBMC obtained from a PPD+ donor is given
Figure 2 IFN-g secretion by PBMC from 3 PPD+ healthy donors in the presence of synthetic 20-mer peptides and rPPE44 (positive
control), as determined by ELISpot. Individual responses to the peptides are indicated as solid, grey and empty bars. Results are expressed as
in Fig. 1A.
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in Figure 5B-C. As can be seen, no reactivity was
detected either against p1L, or against rPPE44 in the
CD4- population of cells. Thus, p1L is recognized by all
PPD+ healthy subjects tested by ELISpot and reactivity
is accounted for by CD4+ cells.
Discussion
The results reported in this paper show that an IFN-g+ T
cell immune response to PPE44 can be detected by ELI-
Spot in all healthy individuals naturally PPD+ and, to a
lower extent, in subjects vaccinated with BCG; CD4+ T
lymphocytes account for IFN-g secretion in PPE44-
responder subjects, as shown by ICC analysis. By the same
approaches, our study has highlighted the presence of a
strong CD4+ T-cell epitope in the NH2-terminus of the
PPE44 molecule localized at the aa position 1-20. Conver-
sely, no significant IFN-g+ CD4+ T cell response to PPE44
or its immunodominant peptide p1L could be detected in
most patients (7 out of 8) with newly diagnosed active TB.
The PPE44 immunodominat T-cell epitope detected in
the present study has been previously reported as the anti-
genic target of an IL-2-induced IFN-g+ response in mice
in which immunization with PPE44-subunit vaccines con-
ferred protective immunity in an experimental model of
TB [10]. The data reported in this paper suggest that IFN-
g+ T-cell responses to PPE44 may be associated to
immune protection also in human M. tuberculosis infec-
tion: indeed, IFN-g+ T-cells specific for the immunodomi-
nant PPE44 peptide p1L were detectable in all individuals
whose immune system is likely to have determined the
containment of infection and prevented progression to
active TB disease (PPD+ healthy subjects), as well as in a
proportion of BCG-vaccinated subjects. On the other
hand, most patients with active TB, i.e., those individuals
whose immune system failed to contain TB infection, did
not respond to PPE44 or p1L. In this respect, however, it
has to be considered that TB patients enrolled in our
study were under TB chemotherapy, which might have
decreased the M. tuberculosis-specific IFN-g responses
[12,13]; another explanation might be that PPE44-specific
T cells are sequestered at the site of mycobacterial replica-
tion, usually the lung. Alternatively, it is tempting to spec-
ulate that the poor T-cell immune responsiveness of TB


























































































































































Figure 3 IFN-g secretion by PBMC from PPD- (A), PPD+ (B) and BCG-vaccinated (C) healthy donors and from patients with active TB (D)
in the presence of p1L, p18L, PPD and ESAT-6, as determined by ELISpot. Results are expressed as in Fig. 1A.
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display due to differential expression of PPE44 during
active infection; indeed, in a previous paper, we reported
great variations in the expression of the gene coding for
PPE44 among M. tuberculosis isolates and that only about
one third of patients with active TB produced antibodies
to PPE44 [14]. A last attractive hypothesis could be that a
T cell response to p1L/PPE44 helpes individuals to contain
TB infection, while those who do not mount such a
response are more prone to develop active disease.
One of the promising features of p1L is that it was
recognized by all 5 PPD+ healthy individuals tested, as
shown by ELISpot, suggesting that p1L is most probably
able to bind a number of human HLA-DR alleles. It also
proved to be immunodominant in two different species,
being a T-cell epitope also in the C57BL/6 strain of mice
[10]. “Promiscuous” helper peptides are peptides that can
bind a wide range of MHC class II alleles. Within their
sequence, they typically have a motif, called P1-P6, where
position 1 can be an aromatic or a hydrophobic aa
whereas position 6 can be a small or hydrophobic aa [15].
Indeed, such motif can be found in 3 positions in p1L,
namely 1-6, 3-8 and 10-6. Promiscuous peptides have
been searched for and described both in mycobacterial
antigens [16] and in other antigens, such as the malarial
circumsporozoite protein [17]. They allow to overcome
the problem of the high degree of polymorphism of the
HLA-DR molecules expressed in the human population
and for such a reason they are ideal candidates for subu-
nit vaccine design and as diagnostic tools. To this aim,
future studies will attempt to establish the HLA class II
restriction elements binding p1L.
Two other PPE proteins of M. tuberculosis have proven
capable of inducing protection against M. tuberculosis in
experimental models, namely i) the PPE14 (Rv0915c/
Mtb41), that has shown promising vaccine potential in
human clinical trials [18], and ii) the PPE18 (Mtb39A/
Rv1196), that is a component of the subunit vaccine
Mtb72F. The latter has recently been investigated in clin-
ical trials showing good tolerability and immunogenicity
in humans [19,20]. Dillon et al. [21] have reported prolif-
erative response towards aa 1-20 of PPE18 in PBMC
from PPD-positive human subjects, that is exactly the
PPE region were our studies have mapped the CD4+ T-
cell epitope. Indeed, the immunodominant p1L domain
shows 60 to 85% aa homology with the corresponding
sequences of 30 PPE proteins of M. tuberculosis and, in
particular, p1L shares 14 identical aa with the NH2-term-
inal 20-aa sequence of the protective antigens PPE18 and
PPE14. These observations raise the possibility that

























































































































Figure 4 IFN-g secretion by PBMC from PPD- (A), PPD+ (B) and BCG-vaccinated (C) healthy donors and from patients with active TB (D)
in the presence of p1L, p18L, PPD and ESAT-6, as determined by ICC flow cytometry. Results are expressed as in Fig. 1B.
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immunogenicity of the conserved and homologous
NH2-terminal regions of the PPE proteins. These consid-
erations make PPE proteins, especially their immunodo-
minant NH2-terminal domains, promising antigen
candidates for TB subunit vaccine development.
Latent TB infection is conventionally screened for by
the more-than-100-year-old tuberculin skin test, that
measures in vivo reactivity to tuberculin or PPD, a mix-
ture of mycobacterial antigens, some of which common
to non-tuberculous mycobacteria and to the vaccine
strain M. bovis BCG. Recently, assays based on release
of IFN-g by PBMC exposed in vitro to M. tuberculosis-
specific antigens, such as ESAT-6 and CFP-10, have
emerged as attractive specific alternatives to tuberculin
skin test to distinguish between M. tuberculosis infec-
tion and BCG vaccination/reactivity to non-tuberculous
mycobacteria [22,23]. However, the sensitivity of both
tuberculin skin test and IFN-g-release assays is subopti-
mal, and none of these tests distinguish between latent
infection and active disease [24]. In this context, PPE44
might turn out as a useful reagent for the immunologi-
cal diagnosis of latent TB and p1L could prove even
more useful than the whole recombinant protein becau-
seT cell reactivity, especially in thawed PBMC, has
often been reported to be higher towards synthetic
peptides than to recombinant proteins [25]. Our data
indicate that a PPE44- or p1L-specific IFN-g+ T cell-
response occurs in naturally PPD+ individuals, who are
likely to harbour latent TB infection, and in a propor-
tion of BCG vaccinees tested, but it is not detectable in
most of our patients with active TB. These results,
although very preliminary, would make p1L a good can-
didate, in association with the other TB-specific anti-
gens available, to distinguish between latent infection
and active disease.
Conclusions
The present report identifies p1L (PPE44 aa 1-20) as an
immunodominant promiscuous peptide that is worth
studiyng further both as a vaccine component and as a
diagnostic reagent.
Methods
Study subjects and ethics statement
Study subjects included 5 purified protein derivative nega-
tive (PPD-) and 5 PPD positive (PPD+) healthy donors, 4
subjects vaccinated with M. bovis BCG (BCG), and 8
patients with active TB, as shown by culture isolation of
M. tuberculosis, recruited from Hospital “SS. Giacomo e
Cristoforo”, Massa, Italy. Reactivity to PPD was deter-
mined on PBMC in vitro by ELISpot. The study was
approved by the Ethics Committee of Hospital “SS. Gia-
como e Cristoforo”, Massa, Italy and written informed
consent was obtained from all subjects.
Figure 5 Representative examples of ICC flow cytometry
analysis of PBMC in response to p1L and rPPE44. The
percentage of IFN-g+ CD4+ cells is given in the upper right corner
of each panel. Panel A, PBMC from a PPD- healthy donor in the
presence of p1L; panel B and C, PBMC of a PPD+ healthy donor in
the presence of p1L and rPPE44, respectively.
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Recombinant PPE44, synthetic peptides, and M.
tuberculosis antigens
rPPE44 was produced in our laboratory; cloning, expres-
sion and purification have been previously reported [9].
A panel of 20-mer peptides, overlapping by 10 aa resi-
dues, spanning the entire 382-aa PPE44 sequence except
for aa 71-80, was synthesized by ProImmune (Oxford,
UK); peptide spanning aa 61-80 could not be synthesized
due to technical reasons; aa sequence and position of pep-
tides are given in Table 1. Peptides were initially dissolved
in DMSO and stock solutions were prepared in RPMI-
1640 medium at 1 mg/ml and stored in aliquots at -20°C
until use.
PPD and ESAT-6 (Early Secretory Antigen T-6) whole
recombinant protein were purchased from Statens
Serum Institut (Copenhagen, Denmark).
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from donors’ heparinized blood by Lympholyte-H (Ceder-
lane, Canada) density gradient centrifugation. Briefly, blood
was layered over an equal volume of Lympholyte-H and
centifuged at 800 g for 30 minutes at room temperature.
The layer of PBMC was removed and washed twice at 500
and 200 g for 10 minutes in RPMI-1640 medium. Cells
were suspended in culture medium consisting of RPMI-
1640 medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin and 10% fetal
calf serum or 3% autologous plasma. All culture reagents
were from Sigma-Aldrich (Milan, Italy)
Enzyme-linked immunospot assay (ELISpot)
The ELISpot reagent kit was purchased from Pierce Bio-
technology (Rockford, USA) and the assay was performed
according to the manufacturers’ recommendations. In
brief, 5 × 104 PBMC in a 50 μl-volume of culture medium
were plated onto multiscreen 96-well polyvinylidene fluor-
ide membrane bottom plates coated with IFN-g-specific
antibody. A 50 μl-volume of medium alone (negative con-
trol), medium containing phorbol 12-myristate 13-acetate
(PMA)/ionomycin (positive control), or test antigens was
added and plates were incubated for 16-24 hr at 37°C in
5% CO2. Test antigens were used at the following final
concentrations: rPPE44, 10 μg/ml; synthetic peptides,
10 μg/ml; PPD, 10 μg/ml; ESAT-6, 5 μg/ml. PMA and
ionomycin were used at 1 ng/ml and 500 ng/ml, respec-
tively. The plates were subsequently washed and incubated
for 1 hr with a biotin-labeled anti-human IFN-g antibody.
After a subsequent wash, the plates were incubated with
alkaline phosphatase-labeled streptavidin for 1 hr and then
developed using a solution of nitro-blue tetrazolium chlor-
ide as substrate. Spots were counted using an automated
image analysis system ELISpot reader (AID, Strassburg,
Germany). Usually, ELISpot results were classified as valid
when spots in wells with medium alone were less than 5
and spots in the presence of PMA/ionomycin were greater
than 20. T-cell responses to tested antigens were classified
as positive when the numbers of spots were greater than 5.
Intracellular cytokine cytometry
Two × 106 PBMC were incubated in polypropylene tubes
in 0.5 ml of culture medium alone (negative control) or
in the same volume of medium containing PMA/ionomy-
cin at final concentrations of 10 ng/ml and 250 ng/ml,
respectively (positive control), or test antigens at the fol-
lowing final concentrations: rPPE44, 1 μg/ml; synthetic
peptides, 1 μg/ml; PPD, 10 μg/ml; ESAT-6, 5 μg/ml.
Costimulatory antibodies CD28 and CD49d (eBioscience,
San Diego, CA, USA) at the concentration of 0.5 μg/ml
were added to all tubes, except for the PMA/ionomycin
tube [26]. After 1-hr activation at 37°C in 5% CO2,
Table 1 Amino acid sequence of synthetic peptides of
PPE44 used in this study
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brefeldin A, 10 μg/ml, (Sigma-Aldrich) was added to each
tube. After a 6-hr incubation, cells were fixed in ice with
1 ml of 1% paraformaldehyde in PBS, washed in FACS
buffer (PBS, 2% FCS, 0,1% NaN3) and permeabilized in
0,1% saponin. Surface and intracellular staining were car-
ried out in the dark for 1 hr with 4 μl PE-labeled anti-
CD4 (Miltenyi Biotec, Bergish Gladbach, Germany) and
0.5 μl FITC-labeled anti-IFN-g (eBioscience) monoclonal
antibodies. Cells were finally washed in FACS buffer/
0.1% saponin, resuspended in FACS buffer and analyzed
by flow cytometry (FACSCan, Becton Dickinson, San
Jose, USA). Viable lymphocytes were gated by forward
and side light scatter and 250,000 CD4+ lymphocytes
events were acquired for each sample and analyzed with
the CellQuest software. The frequencies of CD4+ IFN-g+
events are given as percentages of total CD4+ cells after
subtracting background (% CD4+ IFN-g+ cells in the
negative controls). Values above an arbitrary cut-off of
0.01% CD4+ T cells were classified as positive responses
on the basis of previous studies of CD4+ T-cell responses
to M. tuberculosis antigens [25,27].
Statistical analysis
Fisher exact test was used to compare the numbers of
responders and nonresponders to antigenic stimuli; one-
way analysis of variance with post tests was used to
determine variations among responses. All test were
performed by the InStat software package (GraphPad,
San Diego, CA, USA); P values less than 0.05 were con-
sidered to indicate statistical significance.
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